Published online Feb 7, 2015. doi: 10.3748/wjg.v21.i5.1424
Peer-review started: August 16, 2014
First decision: September 15, 2014
Revised: October 7, 2014
Accepted: November 11, 2014
Article in press: November 11, 2014
Published online: February 7, 2015
Processing time: 177 Days and 10.7 Hours
The high mobility group box 1 (HMGB1), which belongs to the subfamily of HMG-1/-2, is a highly conserved single peptide chain consisting of 215 amino acid residues with a molecular weight of approximately 24894 Da. HMGB1 is a ubiquitous nuclear protein in mammals and plays a vital role in inflammatory diseases. Acute pancreatitis is one of the most common causes of acute abdominal pain with a poor prognosis. Acute pancreatitis is an acute inflammatory process of the pancreas (duration of less than six months), for which the severe form is called severe acute pancreatitis (SAP). More and more studies have shown that HMGB1 has a bidirectional effect in the pathogenesis of SAP. Extracellular HMGB1 can aggravate the pancreatic inflammatory process, whereas intracellular HMGB1 has a protective effect against pancreatitis. The mechanism of HMGB1 is multiple, mainly through the nuclear factor-κB pathway. Receptors for advanced glycation end-products and toll-like receptors (TLR), especially TLR-2 and TLR-4, are two major types of receptors mediating the inflammatory process triggered by HMGB1 and may be also the main mediators in the pathogenesis of SAP. HMGB1 inhibitors, such as ethyl pyruvate, pyrrolidine dithiocarbamate and Scolopendra subspinipes mutilans, can decrease the level of extracellular HMGB1 and are the promising targets in the treatment of SAP.
Core tip: The newly discovered high mobility group box 1 protein is a ubiquitous nuclear protein that exists extensively in mammals. More and more studies have shown its vital role in inflammation. This paper is the first to reveal the bidirectional effect of this protein in the pathogenesis of severe acute pancreatitis and its role as a potential treatment target.